The PDQ cancer information summaries are reviewed regularly and updated as new information becomes available. This section describes the latest changes made to this summary as of the date above.

Relapsed or Refractory Hairy Cell Leukemia

Revised text to state that rituximab can induce durable complete remissions with minimal toxic effects in the majority of patients with relapsing or refractory disease after purine analog therapy or after interferon (cited Angelopoulou et al. as reference 6).

Back to Top

< Previous Section  |  Next Section >